Диссертация (1139867), страница 19
Текст из файла (страница 19)
Lerman A. Endothelial function – Cardiac Events/ Lerman A, Zeither AM /Lerman A. // Circulation.- 2005.- Vol.111.-Р.363–368.142. Li C.Q., Wogan G.N. Nitric oxide as a modulator of apoptosis / Li C.Q.,Wogan G.N //Cancer Lett. 2005.- Vol.226.- P. 1—15.143. Liu, J. Leptinemia and its association with stroke and coronary heart diseasein the Jackson Heart Study / Liu J, Butler KR, Buxbaum SG, Sung JH, CampbellBW, Taylor HA.
// Clin. Endocrinol.- 2010.- Vol.72.-Р. 32–7.144. Lundberg, J.O.Generation From Nitrite and Its Role in Vascular Control /Lundberg J.O., Weitzberg E. //Thromb Vasc Biol.- 2005.- Vol.25.-Р.915-922145. Ludwig D.S. Chaildhood Obesity – The Shape of Things to Come/LudwigD.S. // N Engl J Med .-2007.- Vol.7.- Р. 357 2325.146. Marshall, H.E. Noninvasive stress-induced apoptosis through inhibition ofNF-kappa b / Marshall H.E., Stamler J.S. // J. Biol. Chem.- 2002.- Vol.277.- P.34223—34228.147. Matthew, R.
Noninvasive Measurement of Central Vascular Pressures WithArterial Tonometry: Clinical Revival of the Pulse Pressure Waveform?/ MatthewR. Nelson, Jan Stepanek, at al.// Mayo Clinic Proceedings/ May 2010.- Vol.85.Р.460-472148. Meadows, J.L. Endothelial biology in the post-menopausal obese women/Meadows J.L., Vaughan D.E.// Maturitas .-2011.- Vol. 69.- Р. 120–125149.
Miller, V.M. Vascular actions of estrogens: functional implications/ MillerVM, Duckles SP. // Pharmacol Rev.- 2008.- Vol.60 Р.210–41.150. Mimoun, L. Retinal microvascularisation abnormalities and cardiovascularrisk/Mimoun L, Massin P, Steg G//Arch Cardiovasc Dis.
2009.- May.- Vol.102Р.449-56.128151. Mitrou, P.N. Mediterranean dietary pattern and prediction of all-causemortality in a US population: results from the NIH-AARP Diet and Health Study/Mitrou PN, Kipnis V, Thiebaut AC, et al //Arch Intern Med.-2007.- Vol.167.-P.2461-2468152. Moncada, S.
Does nitric oxide modulate mitochondrial energy generationand apoptosis? / Moncada S., Erusalimsky J.D // Nat. Rev. Mol. Cell. Biol.- 2002.Vol.3.- P. 214—220.153. Moriel, P. Nitric oxide, cholesterol oxides and endothelium-dependentvasodilation in plasma of patients with essential hypertension NO derivatives andcholesterol oxides in hypertension /Moriel P., at al.// Brazilian Journal of Medicaland Biological Research.- 2002.- Vol. 35.- P. 972-986154. Moshage, H. Nitrite and nitrate determination in plasma: a criticalevaluation/ Moshage H., Kok B., Huizenga RR et al.
//Clinical chemistry.-1996.Vol.41.-P. 892-896155. Nakamura, MT Mechanisms of regulation of gene expression by fatty acids /Nakamura MT, Cheon Y, LiY et al //Lipids. – 2004.- Vol.39 .-P.1077-1083156. Nancy, J. Endogenous NO Regulates Plasminogen Activator Inhibitor-1During Angiotensin-Converting Enzyme Inhibition / Nancy J. Brown, James A.S.Muldowney III, Douglas E. Vaughan // Hypertension.- 2006.- Vol.47.-Р.441-448.157.
Nejatizadeh, A. Endothelial nitric oxide synthase gene haplotypes andcirculating nitric oxide levels significantly associate with risk of Essentialhypertension / Nejatizadeh A, Kumar R, Stobdan T, et al // Free Radical Biologyand Medicine.-2008.- Vol.44.- Р.1912–1918158. Nilsson, PMHemodynamic Aging as the Consequence of StructuralChanges Associated with Early Vascular Aging (EVA)/ Nilsson PM// Aging Dis.2014.- Vol.5.- Р.109-13.159. Nurk, E. Changes in lifestyle and plasma total homocysteine: the HordalandHomocysteine Study/Nurk E, Tell GS, Vollset SE, et al.
// Am J Clin Nutr.-2004.Vol.- Р.812-9.129160. O,Keefe, JH. Diabetes Essentials. 4th ed.Sudbury, MA Jones and BartlettPublishers. / O,Keefe JH, Bell DS, Wyne KL //J Am Coll Cardio. – 2009.Vol.191.- P. 277-83161. Oliver, J.J. Stimulated Tissue Plasminogen Activator Release as a Marker ofEndothelial Function in Humans / Oliver J.J., Webb D.J. and Newby D.E. //Arterio.-scler Thromb Vasc Biol.- 2005.- Vol.25 Р.2470-247.162. Orshal, JM. Gender, sex hormones, and vascular tone./ Orshal JM, KhalilRA. // Am J Physiol Regul Integr Comp Physiol.- 2004.- Vol.286.- Р.233–249163. Ozen, S. Assocaition of nitric oxide production and apoptosis in a model ofexperimental nephropathy./ Ozen S., Usta Y.,Orhan D., et al. //Nephrol DialysisTransplantation.
–2001.- Vol.16.- P.32-38164. Park, YW. The metabolic syndrome: prevalence and associated risk factorfindings in the US population from the Third National Health and NutritionExamination Survey 1988–94/ Park YW, Zhu S, Palaniappan L, Heshka S, et al. //Arch Intern Med 2003.- Vol.163.-Р.427–36165. Paul, L. Huang eNOS metabolic syndrome and cardiovascular disease/PaulL. Huang //Trends Endocrinol Metab.- 2009.- Vol.20.- Р.295–302166. Pierdomenico SD Endothelial function in sustained and white coathypertension.
/Pierdomenico SD, Cipollone F, at al// Am J Hypertens.2015.Vol.15.- Р.11-27167. Pou KM. Visceral and subcutaneous adipose tissue volumes are crosssectionally related to markers of inflammation and oxidative stress: theFramingham Heart Study. / Pou KM, Massaro JM, Hoffmann U, et al //Circulation.- 2007; ,-Vol.116Р.1234–41168. Prachi Singh.
Leptin upregulates the expression of plasminogen activatorinhibitor-1 in human vascular endothelial cells / Prachi Singh, Timothy E.Peterson, et al // Biochem Biophys Res Commun.- 2010.- Vol 392.- Р.47–52169. PriyankaShankarishan.EndothelialNitricoxideSynthaseGenPolymorphisms and the Risk of Hypertension in an Indian Population/ PriyankaShankarishan, Prasanta Kumar Borah, Giasuddin Ahmed et al // Biomed Res Int.1302014.- Vol.79.-Р.30-40170. Qiao X. Sex steroids and vascular responses in hypertension and aging /Qiao X, Mc Connell KR, Khalil RA.
// Gender Medicine.-2008.-Vol.5.-Р.46-60171. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration / Radi R. //Proc. Natl. Acad. Sci. USA.- 2004.- Vol.101.- P. 4003—4008.172. Rask-Madsen C. Mechanisms of Disease: Endothelial Dysfunction in insulinresistance and diabetes/ Rask-Madsen C, King GL. //Nat Clin Pract EndocrinolMetab.- 2007.- Vol.15.-Р.346-361.173. Rassaf T.
Plasma nitrosothiols contribute to the systemic vasodilator effectsof intravenously applied NO: experimental and clinical Study on the fate of NO inhuman blood / Rassaf T, Kleinbongard P, Preik M, at al. // Circ Res.- 2002.Vol.91.-Р.470–477.174. Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension:unanswered questions and some speculations / Reckelhoff JF. // Hypertension.2005.- Vol.45.-Р.170–174175.
Reynaert N.L. Nitric oxide represses inhibitory kappaB kinase through Snitrosylation / Reynaert N.L., Ckless K., Korn S.H. et al. // Proc. Natl. Acad. Sc.USA.- 2004.- Vol.4 .-Р.436-441176. Ritt M. Wall-to-lumen ratio of retinal arterioles as a tool to assess vascularchanges./ Ritt M, Schmieder RE// Hypertension.- 2009 .- Vol.54.- Р.384-7177. Roberto M.Lang. Рекомендации по количественной оценке структуры ифункции камер сердца/ Roberto M.Lang, Michelle Bierig, et al.
// Приложение 1к Российскому кардиологическому журналу.- 2012.–Vol. (95) Р. 1-25178. Safaridis PA. Review: Insulin and endothelin: an interplay contributing tohypertension development? / Safaridis PA, Bakris GL.// J Clin Endocrinol Metab.2007.- Vol.92.- Р.379–385.179. Schindler C. The metabolic syndrome as an endocrine disease: is there aneffective pharmacotherapeutic strategy optimally targeting the pathogenesis? /Schindler C.
//Ther Adv Cardiovasc Dis.- 2007.- Vol.1 .- Р.7–26131180. Schulman IH. Interaction between nitric oxide and angiotensin II in theendothelium: role in atherosclerosis and hypertension / Schulman IH, Zhou MS,Raij L.// J Hypertens Suppl.- 2006.- Vol.24.- P. 8945—8950.181. Scridon A. Progressive endothelial damage revealed by multilevel vonWillebrand factor plasma concentration in atrial fibrillation patients / ScridonA., Girerd N., Rugeri L., Nonin- Babary E., Chevalier P. // Europace. 2013.- Vol.15.- Р.1562-6.182. Searles CD. Transcriptional and posttranscriptional regulation of endothelialnitric oxide synthase expression/ Searles CD.
// Am J Physiol Cell Physiol.- 2006.Vol.291.-Р.803-817.183. Sessa WC. Regulation of endothelial derived nitric oxide in health anddisease/ Sessa WC. // Mem Inst Oswaldo Cruz. 2005.- Vol.100.-Р.15-24184. Simão AN. Immunological and biochemical parameters of patients withmetabolic syndrome and the participation of oxidative and nitroative stress/SimãoAN, Lozovoy MA, Simão TN //Braz J Med Biol Res.- 2011.- Vol.44.-Р.707-12.185.
Song D, Arikawa E. Androgens are necessary for the development offructose-induced hypertension. / Song D, Arikawa E, Galipeau D, Battell M,McNeill JH. //Hypertension 2004.- Vol.43.-Р.667–672186. Spiel AO. von Willebrand factor in cardiovascular disease: focus on acutecoronary syndromes / Spiel AO, Gilbert JC, Jilma B //Circulation.- 2008.Vol.117.-Р.1449-59.187. Spencer CG. Von Willebrand factor, soluble P-selectin, and target organdamage in hypertension: a substudy of the Anglo-Scandinavian Cardiac OutcomesTrial (ASCOT)/ Spencer CG, Gurney D et al.// Hypertension.- 2002.- Vol.40.-Р.616.188. Taddei S. Effects of antihypertensive drugs on endothelial dysfunction:clinical implications/ Taddei S, Virdis A, Ghiadoni L et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
